Compare WRLD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | BWAY |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.0M | 674.2M |
| IPO Year | 1994 | N/A |
| Metric | WRLD | BWAY |
|---|---|---|
| Price | $158.01 | $15.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 153.9K | 138.8K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,841,465.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $6.51 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $110.00 | $10.01 |
| 52 Week High | $185.48 | $26.63 |
| Indicator | WRLD | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 42.37 |
| Support Level | $124.56 | $14.56 |
| Resistance Level | $163.80 | $16.63 |
| Average True Range (ATR) | 6.23 | 0.64 |
| MACD | 0.63 | -0.22 |
| Stochastic Oscillator | 97.26 | 18.58 |
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.